Vivani Medical Develops Semaglutide Implant for Weight Management
Vivani Medical is reportedly developing an implant containing semaglutide, the active ingredient found in Novo Nordisk's widely recognized obesity injection Wegovy and its diabetes treatment counterpart, Ozempic. This new implant aims to assist patients in maintaining their weight loss, building on the efficacy of existing GLP-1 receptor agonists.
Vivani Medical is currently developing an innovative implant designed to deliver semaglutide, the key active ingredient in prominent medications like Novo Nordisk's Wegovy and Ozempic.
Semaglutide is a GLP-1 receptor agonist known for its effectiveness in managing both obesity and Type 2 diabetes. Wegovy is specifically approved as an obesity treatment, while Ozempic is prescribed for diabetes management.
This new implant from Vivani Medical represents an effort to provide an alternative method for patients to potentially maintain their weight loss, leveraging the established therapeutic benefits of semaglutide.
According to CNBC Business, the development focuses on creating a convenient and sustained-release option for this widely used compound.
